Instadose Pharma (Instadose Pharma) EV-to-EBIT : -0.56 (As of May. 17, 2024)

Instadose Pharma EV-to-EBIT Chart

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
EV-to-EBIT	Get a 7-Day Free Trial															-0.70	-0.70	-24.78	-3,938.28	-2,380.20

Competitive Comparison of Instadose Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instadose Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's EV-to-EBIT falls into.

Instadose Pharma EV-to-EBIT Calculation

Instadose Pharma's EV-to-EBIT for today is calculated as:

Instadose Pharma's current Enterprise Value is $0.76 Mil.
Instadose Pharma's EBIT for the trailing twelve months (TTM) ended in Feb. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instadose Pharma  (OTCPK:INSD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Instadose Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2022 is calculated as:

Instadose Pharma's Enterprise Value for the quarter that ended in Feb. 2022 was $3,191.79 Mil.
Instadose Pharma's EBIT for the trailing twelve months (TTM) ended in Feb. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instadose Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description